Journal of Medical Imaging and Radiation Oncology最新文献

{"title":"Radiation Therapy Fields of Dreams: We Built Them—But Did They Come?","authors":"Gerard Adams,&nbsp;Tracey Lee Guan,&nbsp;Elizabeth Anne Burmeister,&nbsp;Bryan Henry Burmeister","doi":"10.1111/1754-9485.70099","DOIUrl":"10.1111/1754-9485.70099","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Radiation therapy (RT) has been underused in cancer treatment. One possible reason is the long distances some patients must travel for treatment. We performed this study to investigate whether the introduction of RT treatment facilities in regional locations in Queensland influenced RT utility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The Cancer Alliance Queensland database which links individual patient data to population based and treatment data was used to identify new cancer diagnoses from 2011 to 2020. Cases were grouped according to Local Government Authority (LGA) of residence at the time of diagnosis. Annual use of RT within 12 months of diagnosis (RTU12) for each LGA was calculated. Four regional RT facilities commenced treatment at various points during this time. Variation in year-to-year RTU12 for these LGAs was examined before and after opening and compared to comparable figures for Queensland as well as Brisbane, Townsville and Toowoomba (LGAs with long established centres).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean RTU12 for Queensland was 24.6%, with minimal year-to-year variation. Brisbane, Toowoomba and Townsville LGAs showed stable RTU12 close to the Queensland average. All four regional LGAs without centres in 2010 had lower RTU12 prior to services commencing which improved after installation. For these centres mean RTU12 was 22.1%–95% confidence interval (95% CI) 20.9%–23.3%—before service availability compared to 24.8%–95% CI 24.0% –25.7% (<i>p</i> = 0.03)—after service availability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The installation of regional radiation therapy centers in Queensland appears to be associated with an increase in RT use for patients resident in those LGAs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"462-467"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70099","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Correlation of Quantitative Technetium-99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone-Induced Thyrotoxicosis","authors":"Ray Wang,&nbsp;Nathan Better,&nbsp;Dinesh Sivaratnam,&nbsp;James Westcott,&nbsp;Simon Forehan,&nbsp;David A. Pattison,&nbsp;Spiros Fourlanos","doi":"10.1111/1754-9485.70120","DOIUrl":"10.1111/1754-9485.70120","url":null,"abstract":"&lt;p&gt;Management of amiodarone-induced thyrotoxicosis (AIT) differs according to underlying aetiology. Type 1 AIT (AIT-1) requires antithyroid drugs (ATD) which carry the uncommon risk for hepatotoxicity or agranulocytosis, whilst type 2 AIT (AIT-2) requires prolonged glucocorticoid (GC) treatment with side effects including fluid retention, hyperglycaemia, bone demineralisation, and myopathy. Mixed AIT forms also occur.&lt;/p&gt;&lt;p&gt;Numerous investigation techniques have been suggested to differentiate AIT-1 and AIT-2 [&lt;span&gt;1&lt;/span&gt;]. However, diagnosis remains challenging and the diagnostic utility of thyroid antibodies, ultrasound, colour flow doppler, radioactive iodine scanning and biomarkers such as IL-6 have proven limited or inconsistent. We previously published a case series demonstrating AIT histopathological correlation with imaging involving technetium-99m sestamibi thyroid scintigraphy (&lt;sup&gt;99m&lt;/sup&gt;Tc-STS) [&lt;span&gt;2&lt;/span&gt;]. There is increasing evidence to suggest &lt;sup&gt;99m&lt;/sup&gt;Tc-STS may aid in differentiating AIT types [&lt;span&gt;2-4&lt;/span&gt;], with the quantitatively assessed tracer ‘thyroid-to-background ratio’ (TBR) being inversely related to the degree of inflammatory thyroid destruction. Therefore, we investigated whether &lt;sup&gt;99m&lt;/sup&gt;Tc-STS TBR correlated with ATD and GC treatment duration.&lt;/p&gt;&lt;p&gt;We conducted a retrospective cohort study of all patients with AIT who underwent &lt;sup&gt;99m&lt;/sup&gt;Tc-STS at our hospital between 2013 and 2020. Static anterior planar images of the neck were acquired at 2, 15 and 60 min after intravenous injection of 170–190 MBq of &lt;sup&gt;99m&lt;/sup&gt;Tc-sestamibi (Cardiolite; Lantehus Medical Imaging, Massachusetts, USA) using a 128 × 128 matrix and 2.29 zoom on either Siemens Symbia T16 or E.CAM gamma cameras (Siemens Healthcare, Erlangen, Germany) with low-energy high-resolution collimators. Evaluation of &lt;sup&gt;99m&lt;/sup&gt;Tc-STS TBR was undertaken by nuclear medicine physicians as previously described [&lt;span&gt;5&lt;/span&gt;]. This study was approved by the Melbourne Health Human Research and Ethics Committee (QA2020113), with a waiver of individual consent approved.&lt;/p&gt;&lt;p&gt;Thirty-seven patients with AIT underwent &lt;sup&gt;99m&lt;/sup&gt;Tc-STS, with mean (SD) age 62 (10) years, &lt;i&gt;n&lt;/i&gt; = 31 male, with median (IQR) amiodarone exposure 25 (18, 38) months. Most participants received both ATD and GC (&lt;i&gt;n&lt;/i&gt; = 29), with a minority receiving ATD (&lt;i&gt;n&lt;/i&gt; = 7) or GC (&lt;i&gt;n&lt;/i&gt; = 1) monotherapy. Peak ATD dose was equivalent to a median [IQR] carbimazole dose of 30 mg/day [20, 45], with median [IQR] duration of 5 months [2, 7]. Peak GC dose was equivalent to a median [IQR] prednisolone dose of 40 mg [38, 50], with median [IQR] duration of 5 months (2, 7).&lt;/p&gt;&lt;p&gt;Overall, &lt;sup&gt;99m&lt;/sup&gt;Tc-STS TBR at +2, +15 and +60 min was not significantly correlated with ATD duration (Pearson's &lt;i&gt;r&lt;/i&gt; = 0.14, &lt;i&gt;r&lt;/i&gt; = 0.29, &lt;i&gt;r&lt;/i&gt; = 0.10, respectively) or GC duration (Pearson's &lt;i&gt;r&lt;/i&gt; = −0.14, &lt;i&gt;r&lt;/i&gt; = −0.11, &lt;i&gt;r&lt;/i&gt; = −0.22, respectively).&lt;/p&gt;&lt;p&gt;Ther","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"438-439"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Liver Iron Accumulation With Liver Elastography and Apparent Diffusion Coefficient in Children With Thalassaemia Major","authors":"Murat Kaya,&nbsp;Osman Konukoğlu,&nbsp;Candan Güngör","doi":"10.1111/1754-9485.70084","DOIUrl":"10.1111/1754-9485.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Beta Thalassaemia Major is a hereditary disorder characterised by defective protein synthesis in the beta-globin chain, leading to chronic anaemia. As a consequence of repeated blood transfusions used to manage anaemia, excessive iron accumulation occurs, primarily in the liver and other vital organs, leading to organ damage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To determine the correlation between liver iron concentration and iron accumulation in the liver due to blood transfusions in paediatric patients diagnosed with Beta Thalassaemia Major, using shear wave elastography and liver magnetic resonance imaging apparent diffusion coefficient measurements.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A prospective study was conducted from January 2025 to April 2025 on 77 paediatric patients diagnosed with Beta Thalassaemia Major, utilising liver shear wave elastography, liver apparent diffusion coefficient, T2* values and serum ferritin levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Descriptive statistics for the continuous variables of the patients: elasticity median (10.39 ± 4.39 kPa), velocity median (1.81 ± 0.36 m/s), liver ADC (0.52 ± 0.42), liver T2* (4.93 ± 5.15), LIC (9.45 ± 5.7). The median elasticity values differed significantly across the iron overload severity groups (<i>p</i> = 0.006). A post hoc analysis was performed to identify the groups responsible for this difference. The analysis revealed that the differences originated from comparisons between the mild (9.58 ± 3.62) and severe (14.44 ± 5.91) groups, the moderate (9.47 ± 3.24) and severe (14.44 ± 5.91) groups and the severe (14.44 ± 5.91) and normal (8.16 ± 2.44) groups (<i>p</i>^ac &lt; 0.001; <i>p</i>^bc &lt; 0.001; <i>p</i>^cd = 0.003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We demonstrated a correlation between liver shear wave elastography and liver apparent diffusion coefficient values with MRI T2* and LIC in the group of paediatric patients diagnosed with Beta Thalassaemia Major who had a high liver iron burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"414-420"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium-90 Radioembolisation: A Retrospective Cohort Study of 136 Patients","authors":"Saad Abu Zahra,&nbsp;Muhamad Serhal,&nbsp;Aakash N. Gupta,&nbsp;Ahmed Gabr,&nbsp;Arsalan Nadeem,&nbsp;Ashima Kundu,&nbsp;Daniel Borja-Cacho,&nbsp;Aparna Kalyan,&nbsp;Laura M. Kulik,&nbsp;Amir A. Borhani,&nbsp;Robert J. Lewandowski,&nbsp;Andrew C. Gordon","doi":"10.1111/1754-9485.70107","DOIUrl":"10.1111/1754-9485.70107","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Tumour oxygenation influences the radiobiological effect of yttrium-90 (Y90); thus, baseline hemoglobin (HGB) may affect treatment response. This study evaluated whether baseline HGB is associated with outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC) treated with Y90 transarterial radioembolisation (TARE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analysed 136 ICC patients treated with glass microsphere Y90 from 2004 to 2020, stratified by baseline HGB: ≥ 12 g/dL, 10–11.9 g/dL, and &lt; 10 g/dL. Kaplan–Meier and log-rank tests assessed duration of response (DoR), overall survival (OS), and time to progression (TTP). Lesion response was evaluated by RECIST 1.1. Several clinical and radiologic parameters were evaluated in multivariate Cox models to identify independent OS predictors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean age was similar across HGB groups (~64 years, <i>p</i> = 0.934), and 49% of the cohort was female. Response rates differed significantly: For RECIST 1.1, responders comprised 38% (15/39) (≥ 12 g/dL), 42% (22/53) (10–11.9 g/dL), and 18% (7/39) (&lt; 10 g/dL) (<i>p</i> = 0.041). Median DoR was longest for HGB ≥ 12 g/dL (15.0 months) vs. 6.5 and 6.2 months for 10–11.9 and &lt; 10 g/dL (<i>p</i> = 0.041). TTP varied significantly (7.1, 5.8, and 1.7 months; <i>p</i> = 0.008). Median OS was 17.1, 13.8, and 6.0 months for ≥ 12, 10–11.9, and &lt; 10 g/dL, respectively (<i>p</i> &lt; 0.001). On multivariate analysis, HGB &lt; 10 g/dL remained independently associated with poorer OS (HR 1.83, <i>p</i> = 0.031).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Baseline HGB &lt; 10 g/dL was a predictor of poor antitumor response, earlier progression, and worsened OS in ICC patients undergoing Y90 TARE. HGB is a low-cost, clinically available biomarker that may aid in risk stratification and treatment planning. Future work should assess if risk factor modification prior to TARE (i.e., transfusion for HGB &lt; 10) improves clinical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"447-456"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147773867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of SUVmax on Primary Staging 68Ga-PSMA PET/CT in Determining Metastatic Status of Prostate Cancer","authors":"Geoffrey Liu,&nbsp;Shane Lee,&nbsp;Kabir Ahmad","doi":"10.1111/1754-9485.70081","DOIUrl":"10.1111/1754-9485.70081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>68Ga prostate-specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake. This study aims to assess whether there is a direct relationship between SUVmax of the primary prostate lesion and the presence of nodal and distant metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective review of 265 primary staging 68Ga-PSMA PET/CT studies performed at a single centre on a single PET/CT was performed for the SUVmax of the primary lesion, and the presence of PSMA-avid nodal/distant metastases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analysis shows that a single unit increase in SUVmax of the primary prostatic lesion corresponds with a 1.6% increased odds of nodal metastases, 1.7% increased odds of distant metastases and a 2% increased odds of having either. A single unit increase in the log of the SUVmax corresponds with odds ratios of 2.061, 2.038 and 2.294 respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is a weak but statistically significant correlation between the SUVmax of the primary prostate lesion and the presence of metastases on primary staging 68Ga-PSMA PET/CT for biopsy-proven prostate cancer. However, because the relationship is so weak and the significant overlap in SUVmax in local versus advanced disease, using SUVmax as the sole predictor of advanced disease is unreliable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"407-413"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Performance of Magnetic Resonance Imaging in Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review","authors":"Jeffrey Yong Yau Tai,&nbsp;Aphakorn Hasdarngkul,&nbsp;Ranon Earn Yueh Khoo,&nbsp;Brad Milner","doi":"10.1111/1754-9485.70101","DOIUrl":"10.1111/1754-9485.70101","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Chronic thromboembolic pulmonary hypertension (CTEPH) requires accurate identification of thromboembolic and perfusion defects for diagnosis and operability assessment. Magnetic resonance imaging (MRI) provides radiation-free evaluation of vascular morphology, perfusion distribution and cardiopulmonary function. However, its diagnostic performance in CTEPH has not been comprehensively synthesised.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Purpose&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This review aimed to evaluate the diagnostic accuracy of MRI techniques for detecting chronic thromboembolic material and perfusion defects in CTEPH.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A systematic review was conducted according to PRISMA guidelines and was prospectively registered with PROSPERO (CRD420251134001). PubMed, Medline, Embase and Google Scholar were searched from January 2000 to October 2025 for studies assessing MRI-based detection of CTEPH using accepted reference standards, including computed tomography pulmonary angiography (CTPA), digital subtraction angiography (DSA), ventilation–perfusion (V/Q) scintigraphy or multidisciplinary consensus. Eligible studies evaluated MRI perfusion, contrast-enhanced MR angiography (ce-MRA), non-contrast MRA or advanced MRI techniques in adults with suspected or confirmed CTEPH. Data extraction was performed in duplicate, and the risk of bias was assessed using QUADAS-2. Due to heterogeneity among the included studies, the Synthesis Without Meta-analysis (SWiM) framework was used to guide data synthesis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Nine studies involving 563 participants met the inclusion criteria. Across eight MRI perfusion studies, the median sensitivity was 97% and the median specificity was 92.5%. Standard MRI perfusion demonstrated similar performance (median sensitivity 97%, specificity 92%). Three ce-MRA studies yielded a median sensitivity of 87.7% and specificity of 98.1%. Non-contrast MRA showed lower standalone diagnostic accuracy (sensitivity 45%, specificity 76%) but improved markedly when combined with ce-MRA. Risk of bias was moderate to high across studies, driven primarily by non-consecutive patient selection, variable reference standards and heterogeneity in MRI protocols.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;MRI demonstrates encouraging diagnostic performance for detecting perfusion defects and chronic thromboembolic material in CTEPH, with MRI perfusion offering high sensitivity and ce-MRA showing high specificity. Non-contrast MRA adds value for proximal vessel as","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"421-428"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Innovation to Validation: Strengthening Interventional Radiology Through Data","authors":"Kaiwen Cabbabe,&nbsp;Gerard S. Goh,&nbsp;Charles Li,&nbsp;Matthew Lukies","doi":"10.1111/1754-9485.70109","DOIUrl":"10.1111/1754-9485.70109","url":null,"abstract":"&lt;p&gt;Interventional radiology (IR) is a modern patient-facing clinical speciality, providing both procedural and longitudinal clinical care. The historic model of IR as an expert technical procedural-only service is no longer fit-for-purpose in modern medicine. Innovation with new minimally invasive procedural techniques has been a cornerstone of IR practice and will continue. However, IR has relatively underperformed regarding the production of high-quality clinical data to support practice. To provide the best patient-centred procedural and clinical care, we must foster a culture of rigorous data-driven practice.&lt;/p&gt;&lt;p&gt;Across Australia and New Zealand, physician- and surgical-led specialities continue to dominate research output. This leadership is underpinned by structural advantages, such as competitive training pathways that reward academic output, established research units with dedicated personnel and infrastructure and funded non-clinical time enabling clinicians to undertake research without compromising service delivery. Internationally, National Institutes of Health grant analyses from 2011 to 2020 confirm this, demonstrating that total research funding is overwhelmingly channelled towards physician disciplines, with surgical specialities ranking highly in the total number of grants per active clinician [&lt;span&gt;1&lt;/span&gt;]. Such investment not only facilitates prospective studies but also incentivises sustained engagement in research, contributing to the development of influential clinical registries. A recent landmark Australian example includes the EXTEND-IA TNK trial, which demonstrated Tenecteplase was superior to Alteplase for reperfusion in ischaemic stroke [&lt;span&gt;2&lt;/span&gt;]. Another example is the ongoing Orthopaedic National Joint Replacement Registry, which continues to amass prospective data on arthroplasty patients to track surgical performance, revision rates and patient outcomes [&lt;span&gt;3&lt;/span&gt;]. These examples illustrate the practice-changing power of speciality-driven, prospective data.&lt;/p&gt;&lt;p&gt;By contrast, IR remains a comparatively young speciality which is evolving rapidly, adopting increasing clinical responsibility, longitudinal patient care and complex decision-making roles. Yet despite these advances and the speciality's progress towards formal recognition in Australia and New Zealand, prospective research output has lagged behind that of our more established physician and surgical colleagues. However, the appetite for research is evident in IR. A study by Clements et al. identified 34.7 manuscripts per 100 IR clinicians over a 6-year period, reflecting strong academic interest and output [&lt;span&gt;4&lt;/span&gt;]. However, most Australian IR research remains retrospective, limiting its capacity to influence policy and clinical practice.&lt;/p&gt;&lt;p&gt;Several barriers limit the cultivation of IR-led research. First, as demand for IR services rises, procedural workload and service-delivery pressures frequently displace research activity. T","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"457-461"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147773909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting Embolic Agent Comparisons in Renal Angiomyolipoma Embolisation","authors":"Daniel Westby,&nbsp;Michael G. Curran,&nbsp;Brian M. Moloney","doi":"10.1111/1754-9485.70129","DOIUrl":"10.1111/1754-9485.70129","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"429-430"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Australian MRI Linac Program: From Pie in the Sky to Research Milestone","authors":"Michael Bernard Barton,&nbsp;Geoffrey Paul Delaney,&nbsp;Peter Greer,&nbsp;Lois Holloway,&nbsp;Peter Metcalfe,&nbsp;Robba Rai,&nbsp;Trang Pham,&nbsp;William S. Price,&nbsp;David Waddington,&nbsp;Stuart Crozier,&nbsp;Paul Keall","doi":"10.1111/1754-9485.70133","DOIUrl":"10.1111/1754-9485.70133","url":null,"abstract":"<p>The Australian Magnetic Resonance Imaging (MRI) Linear Accelerator program (MRI linac) was a major research project that aimed to build and test a unique MRI linac prototype for cancer treatment. It aimed to improve radiotherapy anatomical targeting and explore physiological targeting. The purpose of this report is to summarise the development and achievements of the program so as to provide an example of a successful large-scale research project in Australian radiation oncology. The project involved six Australian universities and international collaborators. We developed and built a unique MRI linac configuration comprising a 1 T magnetic field and a 6 MV accelerator, with the beam delivered in line with B₀ and the patient placed across B₀ in the split between the two halves of the magnet. The broad research domains were personalised disease targeting, medical device innovation, and biodiscovery. Specific projects included Artificial Intelligence image enhancement, radiation dosimetry in high magnetic fields, MRI characterisation of cancer heterogeneity in human tumours, and animal and human studies. Over $27 million was obtained to support the program from competitive sources. The program published over 120 papers and supported 25 PhD completions. The learnings from the Australian MRI linac program are that Australia has world-class radiotherapy research in physics and engineering, that major projects need a lot of time and a lot of collaboration, and that large, novel radiotherapy projects can attract significant funding and produce significant results.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"477-486"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and Medium-Term Efficacy of Super-Selective Haemorrhoidal Artery Embolisation for Internal Haemorrhoids and Its Relationship With Severity Grading: A Single-Centre Retrospective Study.","authors":"Hengrui Cai, Hao Zhang, Ruochong Pang, Mingqing Zhang, Wenwen Wang, Liang Yin, Jian Zhang, Jian Jing, Xingwei Sun, Yong Jin","doi":"10.1111/1754-9485.70165","DOIUrl":"https://doi.org/10.1111/1754-9485.70165","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the 12-month symptom relief rate of super-selective haemorrhoidal artery embolisation (HAE) for Grade I-IV internal haemorrhoids and analyse the impact of haemorrhoid grading and embolisation site on treatment efficacy.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 32 patients with internal haemorrhoids who underwent HAE at the Interventional Radiology Department of The Second Affiliated Hospital of Soochow University between April 2020 and January 2025. Efficacy was assessed using Visual Analogue Scale (VAS) and French Bleeding Scale (FBS) scores at 1, 3, 6, and 12 months postoperatively.</p><p><strong>Results: </strong>The clinical success rate at 1 month post-procedure (defined as clinical success: ≥ 50% reduction in VAS or FBS from baseline without requiring any reintervention during follow-up) was 87.5% (28/32). The rates at 3 months, 6 months, and 12 months were 68.8% (22/32), 59.4% (19/32), and 56.2% (18/32). The VAS score decreased from 4.25 ± 1.08 preoperatively to 3.53 ± 1.39 at 1 month postoperatively (p < 0.001), rising to 3.72 ± 1.46 at 12 months postoperatively (p < 0.001). The FBS score decreased from 6.09 ± 1.84 preoperatively to 2.06 ± 1.41 at 1 month postoperatively (p < 0.001), and rebounded to 3.84 ± 2.10 at 12 months postoperatively (p < 0.001). The 12-month efficacy rate remained at 100% for Grade I haemorrhoids, 54.5% for Grade II, 50% for Grade III, and 40% for Grade IV. Minor complications occurred in 9.4% of patients, all resolving without intervention.</p><p><strong>Conclusion: </strong>HAE demonstrates reliable short-term efficacy for bleeding from Grade I-III internal haemorrhoids. As follow-up duration increases and severity grades rise, symptom relief rates gradually decline. The procedure is safe and reproducible, serving as an alternative minimally invasive option for patients unwilling or unable to undergo excision for Grade I-III internal haemorrhoids. However, patients should be informed of the recurrence risk, and long-term efficacy requires further investigation.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}